Ivermectin inhibits ER, HER2, and TGF-beta pathways in ER-positive and endocrine-resistant breast cancer cells. Rujimongkon K, Adchariyasakulchai P, Boonyaratsewee C, Horpratraporn K, et al. PLoS One 2026;21:e0348260.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Rujimongkon K, Adchariyasakulchai P, Boonyaratsewee C, Horpratraporn K, et al. Ivermectin inhibits ER, HER2, and TGF-beta pathways in ER-positive and endocrine-resistant breast cancer cells. PLoS One 2026;21:e0348260.
PMID: 42060658